Skip to content
SPECIFICTION
Get listed

CONVERGE

vergelabs.com

Web
Visit vergelabs.com
Spec score 6.8 #8 of 33 in AI Drug Discovery Software

Spec sheet

Product
CONVERGE is an AI operating system for neuroscience drug development combining foundation models and systems-biology workflows.Read 14 Nov 2026 · vergelabs.com
Support
Verge says it aims to reply to platform and partnership inquiries within two business days.Read 14 Nov 2026 · vergelabs.com
Headquarters
San Francisco, CaliforniaRead 21 Oct 2026 · vergelabs.com
Founded
2015Read 21 Oct 2026 · vergelabs.com
Company
Verge Labs says it started as Verge Genomics in 2015 and became Verge Labs in 2026.Read 14 Nov 2026 · vergelabs.com
Commercial access
Verge describes engagement models ranging from full target-discovery campaigns to focused human-relevance assessments.Read 14 Nov 2026 · vergelabs.com
Data collection
VergeDB is built from brain tissue partnerships and includes transcriptomic, genetic, clinical, and multi-omics data.Read 14 Nov 2026 · vergelabs.com
Model
Its model infers an individual patient's brain molecular state from a routine blood draw and predicts drug response.Read 14 Nov 2026 · vergelabs.com
Program enablement
CONVERGE helps teams evaluate target pathways, patient subgroups, preclinical models, and indication opportunities.Read 14 Nov 2026 · vergelabs.com
Scale
The company's platform data page reports 12,000 brain transcriptomes, 6,000+ neurological patients and controls, and 15M single-cell profiles.Read 14 Nov 2026 · vergelabs.com
Security and integrations
The opened official product pages do not state security certifications or third-party integrations.Read 14 Nov 2026 · vergelabs.com
Target discovery
The platform identifies disease signatures and targets using multimodal patient data and human tissue and genetics.Read 14 Nov 2026 · vergelabs.com
Training data
The foundation model is trained on proprietary multimodal CNS patient data and can be tuned with program- and trial-specific data.Read 14 Nov 2026 · vergelabs.com
Trial optimization
It stratifies trial populations by molecular endotype and identifies likely-benefit subgroups and pharmacodynamic biomarkers.Read 14 Nov 2026 · vergelabs.com
Users
The product is presented for drug developers working on neuroscience and CNS programs.Read 14 Nov 2026 · vergelabs.com

Where Specifiction places it

Alternatives to CONVERGEAll alternatives →